Pharmaceutical Commerce

What National Licensure Means for Wholesalers and 3PLs The Difference Between Meeting DSCSA and Mastering It

Welcome to , a podcast bringing you the latest insights shaping patient access, regulatory policy, and healthcare innovation. I'm your host, and let's get into today's headlines. First up, President Trump announced nine new MFN agreements with manufacturers , bringing the total roster to 26 companies that the administration says now cover 89% of the branded drug market.

McKesson's Scott Mooney discusses the technical and operational challenges of DSCSA compliance, from linking ERP systems to EPCIS to recurring friction in 340B transaction data exchange.

Serialized data exchange under the Drug Supply Chain Security Act (DSCSA) has moved from a compliance mandate to a daily operational reality for wholesale distributors. As part of , we spoke with Scott Mooney, vice president of distribution operations, traceability, at McKesson about the practical side of serialization: linking ERP systems to EPCIS, the industry's uneven progress migrating from GLN to sGLN and the persistent friction points around transaction data.

What National Licensure Means for Wholesalers and 3PLs The Difference Between Meeting DSCSA and Mastering It

A proposed two-year implementation window may sound like ample runway for wholesale distributors and 3PLs to prepare for a national licensure standard. But according to Kala Shankle, vice president, regulatory affairs at the Healthcare Distribution Alliance, that timeline only works if every stakeholder in the system moves in step. In the second installment of her conversation with , ahead of her panel at , Shankle explains why readiness is a coordination problem as much as an operational one.

Complexity in the US healthcare system isn’t new, and neither is the debate over drug costs. What’s changed is the tone. In dozens of conversations we’ve had this year with pharmacy directors at large national and regional health plans, pharmacy benefit managers (PBMs), and integrated delivery networks, we’ve noticed something new: Payers are talking about the growing number of publicly visible drug prices not as background noise, but as leverage.

Independent Pharmacy Cooperative (IPC) has acquired USave Pharmacy Group, effective September 1,1 in a deal that brings together two purchasing organizations that have already worked side by side for nearly a decade.

With the FDA's final rule on 12-digit National Drug Codes now published, the industry has entered what Liberty Dewey, manager, DSCSA at Cardinal Health, calls a planning and preparation phase rather than a full execution phase. spoke with Dewey ahead of her session at , "The Three-Year NDC-12 Transition Period," which examines how stakeholders will operationally manage the shift to NDC-12 as laid out in the final rule.

The biopharmaceutical landscape is in the middle of its most dramatic structural reshuffling in decades. Fueled by record numbers of loss‑of‑exclusivity (LOE) events and pressure from payers to tame specialty‑drug inflation, the industry is watching two very different markets: small‑molecule generics and biosimilars race to define the future of competition. For life sciences leaders, investors and market access strategists, confusing biosimilars with generics is quite common.